Celldex Therapeutics (NASDAQ:CLDX) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a report released on Thursday,Benzinga reports. The firm currently has a $80.00 target price on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a research note on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective on the stock. Wolfe Research lowered shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Citigroup initiated coverage on Celldex Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $70.00 price objective for the company. Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Monday, September 16th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $62.25.

Celldex Therapeutics Stock Performance

CLDX stock traded down $0.14 during trading on Thursday, reaching $26.33. 410,340 shares of the company were exchanged, compared to its average volume of 868,227. The stock’s 50 day moving average price is $33.90 and its 200 day moving average price is $35.90. Celldex Therapeutics has a 52-week low of $24.43 and a 52-week high of $53.18. The company has a market cap of $1.75 billion, a P/E ratio of -10.37 and a beta of 1.60.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.05. The business had revenue of $3.19 million for the quarter, compared to analysts’ expectations of $1.44 million. Celldex Therapeutics had a negative return on equity of 20.41% and a negative net margin of 1,544.32%. As a group, equities research analysts forecast that Celldex Therapeutics will post -2.5 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Celldex Therapeutics in the second quarter valued at approximately $76,000. KBC Group NV grew its stake in shares of Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 495 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Celldex Therapeutics during the 1st quarter valued at $147,000. CANADA LIFE ASSURANCE Co increased its holdings in shares of Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 955 shares during the last quarter. Finally, Ameritas Investment Partners Inc. raised its position in shares of Celldex Therapeutics by 34.3% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 1,582 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.